AbbVie (ABBV) Q3 2024 Earnings
ABBV·Reported October 30, 2024·Before market open
AbbVie reported Q3 2024 revenue of $14.5B, beat analyst consensus of $14.3B by $177.7M. Diluted EPS came in at $3.00, beat the $2.92 consensus by $0.08. AbbVie reports across 2 business segments, led by Biopharmaceutical Products and Aesthetics.
Revenue
$14.5Bbeat by $177.7M
Consensus: $14.3BDiluted EPS
$3.00beat by $0.08
Consensus: $2.92
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about AbbVie's Q3 2024 earnings report.
AbbVie (ABBV) reported Q3 2024 earnings on October 30, 2024 before market open.
AbbVie reported revenue of $14.5B and diluted EPS of $3.00 for Q3 2024.
Revenue beat the consensus estimate of $14.3B by $177.7M. EPS beat the consensus estimate of $2.92 by $0.08.
You can read the 10-Q periodic report (0001551152-24-000040) directly on SEC EDGAR. The filing index links above go to sec.gov.